IGF::OT::IGF DEVELOPMENT OF AN INNOVATIVE PSMA-TARGETED RADIONUCLIDE THERAPY FOR PROSTATE CANCER. PERIOD OF PERFORMANCE: 09/30/2015 - 02/28/2018.

Information

• Research Project
• 9356854

• ApplicationId

  9356854

• Core Project Number

  N43CA000000

• Full Project Number

  261201500074C-4-0-2

• Serial Number

• FOA Number

• Sub Project Id

• Project Start Date

  9/30/2015 - 9 years ago

• Project End Date

  2/28/2018 - 6 years ago

• Program Officer Name

• Budget Start Date

  -

• Budget End Date

  -

• Fiscal Year

  2016

• Support Year

• Suffix

• Award Notice Date

  -

Organizations

• CANCER TARGETED TECHNOLOGY, LLC

Background Information The Phase II of the contract has four objectives: Objective #1: Scale-up and analytical characterization of the lead radiotherapeutic agent selected from Phase I. Objective #2: Optimization of dose/regimen in an animal efficacy model using a PSMA-expressing subcutaneous human prostate tumor. Objective #3: Maximum Tolerate Dose Study of Lead 177Lu-DOTA-PSMA therapeutic agent in normal male rats. Objective #4: Assess safety of the radiolabeled lead agent in an IND-enabling GLP study in adult male rats. Three of these objectives will be pursued by the Subcontractors at University of Pittsburgh.

IC Name

• Activity

  N43

• Administering IC

  CA

• Application Type

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  2000000

• Sub Project Total Cost

• ARRA Funded

  False

• CFDA Code

  395

• Ed Inst. Type

• Funding ICs

  NCI:2000000\

• Funding Mechanism

  SBIR/STTR Contracts

• Study Section

• Study Section Name

• Organization Name

  CANCER TARGETED TECHNOLOGY, LLC

• Organization Department

• Organization DUNS

  829368690

• Organization City

  WOODINVILLE

• Organization State

  WA

• Organization Country

  UNITED STATES

• Organization Zip Code

  980728564

• Organization District

  UNITED STATES